Non-small cell lung cancer
Conditions
Interventions
Reduced-dose Chemotherapy group:Reduced chemotherapy combined with immunotherapy
Sponsors
The Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) 60=1.5L, blood gas analysis PaO2>=70mmHg; (7) Have not received any anti-tumor therapy; (8) Well-controlled underlying diseases such as hypertension, diabetes, hyperthyroidism, and hypothyroidism; (9) Blood system: absolute neutrophil value (ANC) >=2.0×10^9/L, platelet >=100×10^9/L, hemoglobin >=9g/dl; (10) Liver: bilirubin = 60ml/min.
Exclusion criteria
Exclusion criteria: (1) Patients with stage IA or IIIB (T1-2N3) /IIIC or IV NSCLC; (2) Patients with ECOG PS score >=3, who could not tolerate surgery; (3) There are contraindications of chemotherapy, immunotherapy and surgery: active tuberculosis, hepatitis, immune diseases (HIV infection), fungal and bacterial infections, severe coronary artery stenosis, etc. (4) Large cell neuroendocrine carcinoma tumor, carcinosarcoma, carcinoid rare histology; (5) pregnancy or breastfeeding; (6) There are other malignant tumor lesions; (7) The investigator believes that the subject may not be able to complete the study or may not be able to meet the requirements of the study (for administrative reasons or otherwise).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete pathological response; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major pathological response;Disease-free Survival;Overall survival; | — |
Countries
China
Contacts
Public ContactChen Huiguo
The Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed